Trial reportTexas Heart Institute journal2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.
Trial report in Texas Heart Institute journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00684060 (A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction), which is not on this map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Stem cell treatment for acute myocardial infarction.The Cochrane database of systematic reviews · 2015Pooled it
- Guideline
- Long-term effects of autologous bone marrow stem cell treatment in acute myocardial infarction: factors that may influence outcomes.PloS one · 2012Pooled it
- Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β- and IL-6-Related Impairment of Bone Marrow Function.Circulation research · 2017Trial
- Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study.Stem cell research & therapy · 2015Trial
- Trial
- Trial
- Clinical-based Cell Therapies for Heart Disease-Current and Future State.Rambam Maimonides medical journal · 2020Review
- Gadolinium Doping Enhances the Photoacoustic Signal of Synthetic Melanin Nanoparticles: A Dual Modality Contrast Agent for Stem Cell Imaging.Chemistry of materials : a publication of the American Chemical Society · 2019Article
- Development of a Trimodal Contrast Agent for Acoustic and Magnetic Particle Imaging of Stem Cells.ACS applied nano materials · 2018Article
- Concise Review: Mending a Broken Heart: The Evolution of Biological Therapeutics.Stem cells (Dayton, Ohio) · 2017Review
- Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types.NPJ Regenerative medicine · 2017Review
- Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials.Basic research in cardiology · 2017Article
- Myocardial Protection: The Science and Pathophysiology of Myocardial Ischemic Injury.The journal of extra-corporeal technology · 2016Article
- Versatility of Pleuripotent Undifferentiated Stem Cells Aspirated from Bone Marrow and its Applications in Oral and Maxillofacial Surgery.Journal of maxillofacial and oral surgery · 2016Article
- Cardiac stem cell therapy: Have we put too much hype in which cell type to use?Heart failure reviews · 2015Review
- Use of mesenchymal stem cells for therapy of cardiac disease.Circulation research · 2015Review
- Cardiac tissue engineering and regeneration using cell-based therapy.Stem cells and cloning : advances and applications · 2015Review
- Effect of cell origin and timing of delivery for stem cell-based bone tissue engineering using biologically functionalized hydrogels.Tissue engineering. Part A · 2015Article
- Regenerative principles enrich cardiac rehabilitation practice.American journal of physical medicine & rehabilitation · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 1 institution in 1 country.
Funding
Abstract
A realistic goal for cardiac cell therapy may be to attenuate left ventricular remodeling following acute myocardial infarction to prevent the development of congestive heart failure. Initial clinical trials of cell therapy have delivered cells 1 to 7 days after acute myocardial infarction. However, many patients at risk of developing congestive heart failure may not be ready for cell delivery at that time-point because of clinical instability or hospitalization at facilities without access to cell therapy. Experience with cell delivery 2 to 3 weeks after acute myocardial infarction has not to date been explored in a clinical trial. The objective of the LateTIME study is to evaluate by cardiac magnetic resonance the effect on global and regional left ventricular function, between baseline and 6 months, of a single intracoronary infusion of 150 × 106 autologous bone marrow mononuclear cells (compared with placebo) when that infusion is administered 2 to 3 weeks after moderate-to-large acute myocardial infarction. The 5 clinical sites of the Cardiovascular Cell Therapy Research Network (CCTRN) will enroll a total of 87 eligible patients in a 2:1 bone marrow mononuclear cells-to-placebo patient ratio; these 87 will have undergone successful percutaneous coronary intervention of a major coronary artery and have left ventricular ejection fractions ≤0.45 by echocardiography. When the results become available, this study should provide insight into the clinical feasibility and appropriate timing of autologous cell therapy in high-risk patients after acute myocardial infarction and percutaneous coronary intervention.
Indexed as
Identifiers
20844613PMC2929864W1543452484What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.